Cargando…

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Objectives To determine the incremental net health benefits of dabigatran etexilate 110 mg and 150 mg twice daily and warfarin in patients with non-valvular atrial fibrillation and to estimate the cost effectiveness of dabigatran in the United Kingdom. Design Quantitative benefit-harm and economic a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pink, Joshua, Lane, Steven, Pirmohamed, Munir, Hughes, Dyfrig A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204867/ https://www.ncbi.nlm.nih.gov/pubmed/22042753 http://dx.doi.org/10.1136/bmj.d6333

Ejemplares similares

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
por: Liu, Ya-ou, et al.
Publicado: (2022)

The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013)

Dabigatran etexilate tetrahydrate
por: Liu, Hong-Qiang, et al.
Publicado: (2012)

Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
por: Huber, K, et al.
Publicado: (2013)

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
por: Kansal, Anuraag R, et al.
Publicado: (2012)

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients
por: Ellis, Christopher R, et al.
Publicado: (2013)

Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin
por: Fonseca, Eileen, et al.
Publicado: (2015)

New options with dabigatran etexilate in anticoagulant therapy
por: Maegdefessel, Lars, et al.
Publicado: (2010)

Dabigatran-etexilate: Lack of efficacy: case report
Publicado: (2021)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial
por: Yoshida, Yukihiko, et al.
Publicado: (2018)

Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation
por: Simpson, Bryan H., et al.
Publicado: (2019)

FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
por: J, Aalbers, et al.
Publicado: (2010)

Recovery of Visual Function after Administration of Dabigatran Etexilate
por: Schönfeld, Carl-Ludwig, et al.
Publicado: (2014)

Dabigatran etexilate: Cholestatic liver injury: case report
Publicado: (2021)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial
por: Yu, Yi-bo, et al.
Publicado: (2018)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Choice of Renal Function Estimator Influences Adverse Outcomes with Dabigatran Etexilate in Patients with Atrial Fibrillation
por: Simpson, Bryan H., et al.
Publicado: (2018)

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial
por: Ferro, José M., et al.
Publicado: (2019)

The effects of dabigatran etexilate on fracture healing in rats: An experimental study
por: Kerimoglu, Servet, et al.
Publicado: (2015)

Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate
por: Kızılırmak, Filiz, et al.
Publicado: (2016)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
por: Clemens, Andreas, et al.
Publicado: (2012)

Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
por: Bellamy, L, et al.
Publicado: (2009)

The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency
por: Gribkova, Irina V., et al.
Publicado: (2016)

Effectiveness and Safety of Dabigatran and Warfarin in Real‐World US Patients With Non‐Valvular Atrial Fibrillation: A Retrospective Cohort Study
por: Lauffenburger, Julie C., et al.
Publicado: (2015)

Anticoagulation efficacy of dabigatran etexilate for left atrial appendage thrombus in patients with atrial fibrillation by transthoracic and transesophageal echocardiography
por: Xing, Xiao Fei, et al.
Publicado: (2018)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation
por: Benamer, Sufyan, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

What neurosurgeons need to know about dabigatran etexilate (pradax(®)/pradaxa(®)/prazaxa(®))
por: Dwyer, Christopher Michael, et al.
Publicado: (2015)

The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
por: Brent, Mikkel Bo, et al.
Publicado: (2017)

In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate
por: Aljohani, Maher M., et al.
Publicado: (2018)

Extremely Elevated International Normalized Ratio in a Patient with Dabigatran Etexilate Use
por: Memon, Waqas, et al.
Publicado: (2019)

Apixaban/dabigatran etexilate/enoxaparin sodium: Various toxicities: 8 case reports
Publicado: (2022)

Rhabdomyolysis happened after the start of dabigatran etexilate treatment: A case report
por: Zheng, Tingting, et al.
Publicado: (2022)

Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n2enquajk6gnt7o5nl4re5csfo